BPS 2018 Proceedings

BPS 2018 Proceedings

Young Investigator Keynote address

Jevgenij Raskatov

Assistant Professor in Biochemistry and Chemistry
University California Santa Cruz

Chirality, Alzheimer’s Disease, and Amyloid Beta

Peptide Showcase

Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or  therapeutic being offered and the business strategy.

Melvin Klegerman

Professor
University of Texas Health Science Center at Houston

A Fibrin-Binding Peptide for Targeting Drug-Loaded Liposomes to Atherosclerotic Plaques

Michael Coe

Chief Scientific Officer
Phoreus Biotechnology, Inc.

Redefining Bio-Delivery with Peptide Nanotechnology

Jennifer Neff

Jennifer
Allvivo Vascular

Engineered antimicrobial peptides and their application to prevent medical device associated infections

Amit Michaeli

CTO
Pepticom Ltd.

Ab initio Computational Peptide Discovery: Concepts and Examples.

Mark McLaughlin

Mark
Modulation Therapeutics Inc

225Ac-DOTA-MC1RL as a novel therapy for metastatic uveal melanoma

David Guay

David
Feldan Therapeutics

Novel peptide technology to deliver proteins and CRISPR ribonucleoproteins in cells

Richard Liggins

CSO
Zucara Therapeutics

ZT-01, a First in Class Drug to Prevent Hypoglycemia in Type 1 Diabetes

Martin Handfield

Senior VP, Research
Oragenics

Lantibiotics for the Treatment of Clostridium difficile Associated Disease

Mark Edelsward

Director of Business Development
PharmaIN Corp.

PharmaIN makes Peptides better! PharmaIN leverages proprietary platforms for API enhancement and delivery

Meredith Hay

Founder and CSO
ProNeurogen

Glycoslyated Angiotensin 1-7 as novel treatment for cognitive impairment

Laurie Broadwater

Head of Analytical Chemistry
Thermalin Inc

Reducing the Burden of Insulin Therapy

Dwight Morrow

VP Preclinical Development
Magenta Therapeutics

Rapid and Robust Mobilization of Hematopoietic Stem Cells With MGTA-145: A Truncated Protein Variant of the Chemokine CXCL2

Carola Leuschner

Consultant for Intendet Services
Intendet Services LLC

Novel peptides for immune stimulation and synergy with checkpoint inhibitors

Maria Soloveychik

CEO
SyntheX

Cell based production and selection of PPI-modulating peptides and applications in oncology.

Philip Kim

Associate Professor
University of Toronto

Method to generate highly stable D-amino acid analogs of bioactive helical peptides using a mirror image of the entire PDB

Research Showcase

Brief 15 minute presentations of applied research from the academic labs.

Gerardo Byk

Gerardo
Bar Ilan University

Novel peptide isolated from Middle Asian Tortoise spleen extract induces repopulation of mice bone marrow after irradiation.

Jack Henkin

Research Professor, Chemistry, Center for Developmental Therapuetics
Northwestern University

Peptides enabling extended intravitreal drug delivery as nano-particle conjugates

Tambet Teesalu

Professor
University of Tartu, Estonia

Tumor penetrating peptides: discovery and clinical development

Peptides in the Clinic

Updates on clinical development of peptide therapeutics.

Dieter Willbold

Dieter
Forschungszentrum Jülich

PD, PK and target engagement of the orally available all-D-enantiomeric peptide PRI-002 developed for causal therapy of Alzheimer’s disease using direct Aβ oligomer elimination as MoA

Bernhard Fischer

CEO
APEPTICO

Design and clinical application of SOLNATIDE, a new peptide for treatment of critical pulmonary dysfunctions

Nazli Azimi

Founder, President and CEO
Bioniz Therapeutics

Characterization of a Novel, Multi-Cytokine Inhibitor, BNZ-1, for the Treatment of T-cell Malignancies and Alopecia Areata

Emmanuel Dauty

Head of the Physical Chemistry Department
Adocia Inc

Overcoming Formulation and Administration Challenges of Biomolecules BioChaperone® Technology: a Platform to Improve Solubility and Stability of Proteins and Peptides

Ashok Bhandari

Ashok
Protagonist Therapeutics

PTG-300, AN HEPCIDIN MIMETIC PEPTIDE FOR TREATMENT OF INEFFECTIVE ERYTHROPOIESIS AND CHRONIC ANEMIA IN HEMOGLOBINOPATHY DISEASES

Steven Prestrelski

Chief Scientific Officer
Xeris Pharmaceuticals, Inc.

XeriSol Formulation Technology for Stable Peptide Injectables

Andy Parker

CSO
Zealand Pharma

Dasiglucagon, a novel ready-to-use glucagon analog in development for treatment of severe hypoglycaemia

Drug Delivery

Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies

Harald Rau

Chief Scientific Officer
Ascendis Pharma

TransCon technology for sustained delivery of proteins, peptides, and small molecules

Becky Nofsinger

Becky
Merck

Novel Approaches for Evaluating and Enhancing Oral Absorption of Peptides

Kennett Sprogøe

Senior Vice President, Product Innovation
Ascendis Pharma

TransCon technology for sustained delivery of proteins, peptides, and small molecules

Ernest Giralt

Professor
IRB Barcelona

Peptides for molecular recognition and brain delivery

Sheauyu Hsu

Sheauyu Teddy
Adepthera

Development of a novel peptide-centric sustained release system

Advances in Chemistry

Erika Olson

Postdoctoral Researcher
Harvard Medical School

Rational Development of a Peptide Antagonist for EphA4, a Cell-Surface Receptor Linked to Neurodegeneration

James Nowick

Professor and Department Chair
University of California, Irvine, Department of Chemistry

Unlocking the Mysteries of Amyloid Diseases with Macrocyclic β-Sheet Peptides

Lin Yan

Principal Scientist
Merck & Co., Inc.

Synthesis and Characterization of Glucose Responsive Insulins

Phil Dawson

Professor
TSRI

Peptide macrocycle conformational engineering using a rigid, linear linker

Carrie Haskell-Luevano

Carrie
University of Minnesota

Peptide GPCR Dimers: opportunities for drug design and chemical probe discovery

Megan Thielges

Megan
Indiana University

Site-Specific Infrared Spectroscopy of Conformational Heterogeneity in Proline-Rich Motif Recognition

Erika Olson

Postdoctoral Researcher
Harvard Medical School

Rational Development of a Peptide Antagonist for EphA4, a Cell-Surface Receptor Linked to Neurodegeneration

James Nowick

Professor and Department Chair
University of California, Irvine, Department of Chemistry

Unlocking the Mysteries of Amyloid Diseases with Macrocyclic β-Sheet Peptides

Lin Yan

Principal Scientist
Merck & Co., Inc.

Synthesis and Characterization of Glucose Responsive Insulins

Phil Dawson

Professor
TSRI

Peptide macrocycle conformational engineering using a rigid, linear linker

Carrie Haskell-Luevano

Carrie
University of Minnesota

Peptide GPCR Dimers: opportunities for drug design and chemical probe discovery

Megan Thielges

Megan
Indiana University

Site-Specific Infrared Spectroscopy of Conformational Heterogeneity in Proline-Rich Motif Recognition

Information for BPS Presenters

The Boulder Peptide Foundation was established to further the science and knowledge of peptide technology to develop novel therapeutics, biomaterials, medical diagnostics and other beneficial uses for mankind. As part of this goal we run several programs to support career advancement, seminars and educational events. Join us on our mission to expand the applications of peptide science.

Information for BPS Presenters

The purpose of the Boulder Peptide Symposium is to encourage sharing of information related to peptide therapeutic development with an emphasis on the technical, scientific and regulatory aspects of the pharmaceutical development. Presentations that demonstrate original thinking or share experiences from case studies in product development shall receive priority over others.

The Boulder Peptide Symposium offers multiple opportunities for participants to present.

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.